{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:34:48Z","timestamp":1793892888000,"version":"4.8.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":236,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.gastha.2026.101109","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T15:35:05Z","timestamp":1788017705000},"page":"101109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Vedolizumab on Bowel Urgency in Ulcerative Colitis: Post Hoc Analysis of the GEMINI 1, VISIBLE 1, and VARSITY Trials"],"prefix":"10.1016","volume":"5","author":[{"given":"Angelina E.","family":"Collins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thais","family":"Gift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastha.2026.101109_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.651415","article-title":"Novel and emerging therapies for inflammatory bowel disease","volume":"12","author":"Al-Bawardy","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.gastha.2026.101109_bib2","doi-asserted-by":"crossref","first-page":"13780","DOI":"10.1073\/pnas.0706625104","article-title":"Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases","volume":"104","author":"Frank","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.gastha.2026.101109_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231163118","article-title":"Can we change the natural course of inflammatory bowel disease?","volume":"16","author":"Le Berre","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.gastha.2026.101109_bib4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.5114\/aoms.2016.59254","article-title":"Indirect costs of inflammatory bowel diseases: crohn's disease and ulcerative colitis. A systematic review","volume":"12","author":"Kawalec","year":"2016","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.gastha.2026.101109_bib5","doi-asserted-by":"crossref","first-page":"5862","DOI":"10.3748\/wjg.v25.i38.5862","article-title":"Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil","volume":"25","author":"Parra","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastha.2026.101109_bib6","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/ecco-jcc\/jjae057","article-title":"Work productivity impairment in persons with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"18","author":"Youssef","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastha.2026.101109_bib7","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.14309\/ajg.0000000000002404","article-title":"Bowel urgency in ulcerative colitis: current perspectives and future directions","volume":"118","author":"Dubinsky","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastha.2026.101109_bib8","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.cgh.2023.02.029","article-title":"Identifying, understanding, and managing fecal urgency in inflammatory bowel diseases","volume":"21","author":"Caron","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2026.101109_bib9","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/ibd\/izae044","article-title":"Patient perspectives of bowel urgency and bowel urgency-related accidents in ulcerative colitis and crohn's disease","volume":"30","author":"Jairath","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastha.2026.101109_bib10","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/0016-5085(87)90255-1","article-title":"Anorectal sensitivity and responses to rectal distention in patients with ulcerative colitis","volume":"93","author":"Rao","year":"1987","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2026.101109_bib11","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/ibd\/izad142","article-title":"The Communicating Needs and Features of IBD Experiences (CONFIDE) study: US and European patient and health care professional perceptions of the experience and impact of symptoms of moderate-to-severe ulcerative colitis","volume":"30","author":"Travis","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastha.2026.101109_bib12","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/ibd\/izab016","article-title":"Ulcerative colitis narrative global survey findings: the impact of living with ulcerative colitis-patients' and physicians' view","volume":"27","author":"Dubinsky","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastha.2026.101109_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000505092","article-title":"Ulcerative colitis: disease burden, impact on daily life, and reluctance to consult medical professionals: results from a Japanese internet survey","volume":"5","author":"Hibi","year":"2020","journal-title":"Inflamm Intest Dis"},{"key":"10.1016\/j.gastha.2026.101109_bib14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/PROM.S378759","article-title":"Exploring disease remission and bowel urgency severity among adults with moderate to severe ulcerative colitis: a qualitative study","volume":"13","author":"Dubinsky","year":"2022","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.gastha.2026.101109_bib15","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastha.2026.101109_bib17","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s41687-022-00522-2","article-title":"Psychometric evaluation of the urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis","volume":"6","author":"Dubinsky","year":"2022","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.gastha.2026.101109_bib18","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/apt.15726","article-title":"Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis","volume":"51","author":"Dulai","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastha.2026.101109_bib19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s41687-018-0049-2","article-title":"Development and validation of the Ulcerative Colitis patient-reported outcomes signs and symptoms (UC-pro\/SS) diary","volume":"2","author":"Higgins","year":"2017","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.gastha.2026.101109_bib20","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/ibd\/izaa193","article-title":"Tofacitinib in patients with ulcerative colitis: inflammatory bowel disease questionnaire items in phase 3 randomized controlled induction studies","volume":"27","author":"Dubinsky","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastha.2026.101109_bib21","doi-asserted-by":"crossref","first-page":"i1816","DOI":"10.1093\/ecco-jcc\/jjad212.1140","article-title":"P1010 guselkumab improves abdominal pain and bowel urgency symptoms in patients with moderately to severely active ulcerative colitis: results from the phase 3 QUASAR induction study","volume":"18","author":"Rubin","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastha.2026.101109_bib22","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0016-5085(89)80080-0","article-title":"A new measure of health status for clinical trials in inflammatory bowel disease","volume":"96","author":"Guyatt","year":"1989","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2026.101109_bib23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3390\/medicina58040486","article-title":"Health-related quality of life in patients with inflammatory bowel disease in clinical remission: what should we look for?","volume":"58","author":"Stroie","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.gastha.2026.101109_bib24","doi-asserted-by":"crossref","first-page":"i339","DOI":"10.1093\/ecco-jcc\/jjac190.0316","article-title":"P186 impact of tofacitinib maintenance therapy on key ulcerative colitis patient-reported outcomes of fatigue, urgency, abdominal pain and sexual dysfunction using IBDQ and SF-36 individual items as proxies","volume":"17","author":"Dubinsky","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastha.2026.101109_bib26","series-title":"Prescribing information, Entyvio","year":"2022"},{"key":"10.1016\/j.gastha.2026.101109_bib27","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastha.2026.101109_bib28","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2026.101109_bib29","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastha.2026.101109_bib30","first-page":"688","article-title":"Comparison of clinical improvement as measured by two quality-of-life indexes: a pooled analysis of vedolizumab randomized clinical trials in inflammatory bowel disease","volume":"10","author":"Louis","year":"2022","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.gastha.2026.101109_bib31","doi-asserted-by":"crossref","first-page":"i2192","DOI":"10.1093\/ecco-jcc\/jjae190.1386","article-title":"P1212 effectiveness of vedolizumab to reduce bowel urgency in a Canadian real-world ulcerative colitis cohort","volume":"19","author":"Battat","year":"2025","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastha.2026.101109_bib32","article-title":"Fecal incontinence in inflammatory bowel disease","volume":"3","author":"Kamal","year":"2021","journal-title":"Crohn's Colitis 360"},{"key":"10.1016\/j.gastha.2026.101109_bib33","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/ueg2.12657","article-title":"Fecal urgency and incontinence in inflammatory bowel disease perceived by physician and patient: results from the Swiss fecal urgency survey","volume":"13","author":"Wespi","year":"2025","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.gastha.2026.101109_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.gastha.2025.100796","article-title":"Bowel urgency severity among patients with crohn's disease or ulcerative colitis on advanced therapies: real-world data using study of a prospective adult research cohort with inflammatory bowel disease","volume":"4","author":"Lewis","year":"2025","journal-title":"Gastro Hep Adv"},{"key":"10.1016\/j.gastha.2026.101109_bib35","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000669","article-title":"Clinical long-term outcomes of patient-reported outcomes in the prospective real-world tofacitinib response in ulcerative colitis registry","volume":"15","author":"Herfarth","year":"2024","journal-title":"Clin Translational Gastroenterol"},{"key":"10.1016\/j.gastha.2026.101109_bib36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12876-020-01332-w","article-title":"Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review","volume":"20","author":"Helwig","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.gastha.2026.101109_bib37","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1093\/ibd\/izy155","article-title":"Effectiveness and safety of vedolizumab in anti-TNF-na\u00efve patients with inflammatory bowel disease-a multicenter retrospective European study","volume":"24","author":"Kopylov","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastha.2026.101109_bib38","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s10620-021-06907-5","article-title":"Predictors of response to vedolizumab in patients with ulcerative colitis: results from the Greek VEDO-IBD cohort","volume":"67","author":"Bamias","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastha.2026.101109_bib39","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/apt.14930","article-title":"Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry","volume":"48","author":"Chaparro","year":"2018","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277257232600230X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277257232600230X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:17:54Z","timestamp":1793891874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S277257232600230X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"alternative-id":["S277257232600230X"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2026.101109","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Vedolizumab on Bowel Urgency in Ulcerative Colitis: Post Hoc Analysis of the GEMINI 1, VISIBLE 1, and VARSITY Trials","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2026.101109","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Takeda Pharmaceuticals USA, Inc.. Published by Elsevier Inc on behalf of American Gastroenterological Association.","name":"copyright","label":"Copyright"}],"article-number":"101109"}}